votrient
novartis new zealand ltd - pazopanib hydrochloride 216.7mg equivalent to 200 mg pazopanib base; ; - film coated tablet - 200 mg - active: pazopanib hydrochloride 216.7mg equivalent to 200 mg pazopanib base excipient: magnesium stearate microcrystalline cellulose opadry pink ys-1-14762-a povidone sodium starch glycolate - votrient is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (rcc).
votrient
novartis new zealand ltd - pazopanib hydrochloride 433.4mg equivalent to 400 mg pazopanib base; ; - film coated tablet - 400 mg - active: pazopanib hydrochloride 433.4mg equivalent to 400 mg pazopanib base excipient: magnesium stearate microcrystalline cellulose opadry white ys-1-7706-g povidone sodium starch glycolate - votrient is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (rcc).
duavive
pfizer new zealand limited - bazedoxifene acetate 22.56mg equivalent to 20mg bazedoxifene - in tablet subcoat; ; conjugated estrogens 0.45mg (10.4895 mg conjugated estrogens (ce) dessication with lactose (containing 4.29% ce) - in tablet core); - modified release tablet - 0.45mg/20mg - active: bazedoxifene acetate 22.56mg equivalent to 20mg bazedoxifene - in tablet subcoat conjugated estrogens 0.45mg (10.4895 mg conjugated estrogens (ce) dessication with lactose (containing 4.29% ce) - in tablet core) excipient: ascorbic acid hyprolose hypromellose isopropyl alcohol lactose monohydrate macrogol 400 magnesium stearate microcrystalline cellulose opacode black ns-78-17821 opadry pink 03b14899 opaglos clear 98z19173 purified water sucrose sucrose palmitate - duavive is indicated for treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate. the experience treating women older than 65 years is limited.
indomethacin agila
viatris limited - indometacin sodium trihydrate 1.061mg equivalent to indomethacin 1 mg - powder for injection - 1 mg - active: indometacin sodium trihydrate 1.061mg equivalent to indomethacin 1 mg - indomethacin is indicated for the closure of patent ductus arteriosus in premature babies. clear-cut clinical evidence of a haemodynamically significant patent ductus arteriosus should be present, such as respiratory distress, a continuous murmur, a hyperactive precordium, cardiomegaly and pulmonary plethora on chest x-ray. indomethacin should only be used in a hospital under supervision of a specialist neonatologist.
indomethacin iv mylan
viatris limited - indometacin sodium trihydrate 1.061mg equivalent to indomethacin 1 mg - powder for injection - 1 mg - active: indometacin sodium trihydrate 1.061mg equivalent to indomethacin 1 mg - indomethacin is indicated for the closure of patent ductus arteriosus in premature babies. clear-cut clinical evidence of a haemodynamically significant patent ductus arteriosus should be present, such as respiratory distress, a continuous murmur, a hyperactive precordium, cardiomegaly and pulmonary plethora on chest x-ray. indomethacin should only be used in a hospital under supervision of a specialist neonatologist.
sutent
pfizer new zealand limited - sunitinib malate 50.1mg equivalent to 37.5mg sunitinib; - capsule - 37.5 mg - active: sunitinib malate 50.1mg equivalent to 37.5mg sunitinib excipient: croscarmellose sodium gelatin ink iron oxide yellow magnesium stearate mannitol povidone sodium laurilsulfate titanium dioxide - sutent is indicated for the treatment of advanced renal cell carcinoma.
trinomia
te arai biofarma limited - aspirin 100mg (2 x 50mg); ; atorvastatin calcium trihydrate 21.69mg (2 x 10.845mg (equivalent to 20mg atorvastatin)); ; ramipril 10mg; - combination capsule - 100mg/20mg/10mg - active: aspirin 100mg (2 x 50mg) excipient: microcrystalline cellulose opadry white oy-b-28920 amb purified talc sodium starch glycolate active: atorvastatin calcium trihydrate 21.69mg (2 x 10.845mg (equivalent to 20mg atorvastatin)) excipient: calcium carbonate colloidal silicon dioxide crospovidone hyprolose lactose monohydrate magnesium stearate opadry green 06o21881 polysorbate 80 pregelatinised maize starch active: ramipril 10mg excipient: hypromellose microcrystalline cellulose opadry yellow sodium stearyl fumarate starch black ink (trinomia) gelatin iron oxide red titanium dioxide - trinomia is indicated for the secondary prevention of cardiovascular accidents as substitution therapy in adult patients adequately controlled with the mono-components given concomitantly at equivalent therapeutical doses
trinomia
te arai biofarma limited - aspirin 100mg (2 x 50mg); ; atorvastatin calcium trihydrate 21.69mg (2 x 10.845mg (equivalent to 20mg atorvastatin)); ; ramipril 2.5mg; - combination capsule - 100mg/20mg/2.5mg - active: aspirin 100mg (2 x 50mg) excipient: microcrystalline cellulose opadry white oy-b-28920 amb purified talc sodium starch glycolate active: atorvastatin calcium trihydrate 21.69mg (2 x 10.845mg (equivalent to 20mg atorvastatin)) excipient: calcium carbonate colloidal silicon dioxide crospovidone hyprolose lactose monohydrate magnesium stearate opadry green 06o21881 polysorbate 80 pregelatinised maize starch active: ramipril 2.5mg excipient: hypromellose microcrystalline cellulose opadry yellow 80w32039 sodium stearyl fumarate starch black ink (trinomia) gelatin iron oxide black titanium dioxide - trinomia is indicated for the secondary prevention of cardiovascular accidents as substitution therapy in adult patients adequately controlled with the mono-components given concomitantly at equivalent therapeutical doses
trinomia
te arai biofarma limited - aspirin 100mg (2 x 50mg); ; atorvastatin calcium trihydrate 21.69mg (2 x 10.845mg (equivalent to 20mg atorvastatin)); ; ramipril 5mg; - combination capsule - 100mg/20mg/5mg - active: aspirin 100mg (2 x 50mg) excipient: microcrystalline cellulose opadry white oy-b-28920 amb purified talc sodium starch glycolate active: atorvastatin calcium trihydrate 21.69mg (2 x 10.845mg (equivalent to 20mg atorvastatin)) excipient: calcium carbonate colloidal silicon dioxide crospovidone hyprolose lactose monohydrate magnesium stearate opadry green 06o21881 polysorbate 80 pregelatinised maize starch active: ramipril 5mg excipient: hypromellose microcrystalline cellulose opadry yellow sodium stearyl fumarate starch black ink (trinomia) gelatin iron oxide black iron oxide red titanium dioxide - trinomia is indicated for the secondary prevention of cardiovascular accidents as substitution therapy in adult patients adequately controlled with the mono-components given concomitantly at equivalent therapeutical doses
velphoro sucroferric oxyhydroxide 2500 mg (equivalent to iron 500 mg) chewable tablet bottle
seqirus pty ltd - sucroferric oxyhydroxide, quantity: 2500 mg - tablet, chewable - excipient ingredients: colloidal anhydrous silica; neohesperidin-dihydrochalcone; magnesium stearate; flavour - velphoro is indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease (ckd) on dialysis.